Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
Jovana Y MartinRenata R UrbanJohn B LiaoBarbara A GoffPublished in: Journal of gynecologic oncology (2016)
The use of bevacizumab in heavily pretreated EOC, FTC, or PPC is worth consideration.